What to expect.
- Triple-receptor mechanism (GIP, GLP-1, and glucagon) for a broader metabolic effect than dual-agonist therapies
- The largest weight-loss results reported to date for an agent in this class, with Phase 2 data showing up to 24% body weight reduction at 48 weeks
- Glucagon receptor activation increases energy expenditure and promotes fat breakdown, rather than relying on appetite suppression alone
- Meaningful improvements in blood sugar control (HbA1c) among trial participants with type 2 diabetes
- Reduction in liver fat, with potential benefit for metabolic-associated fatty liver disease (MASLD)
- Improvements in blood pressure and lipid profile markers among trial participants
Dr. Taylor's take
“Retatrutide's triple-agonist mechanism, adding glucagon receptor activation to the GIP and GLP-1 combination, is producing some of the most striking weight-loss data I've seen in clinical trials to date. The glucagon component is the real differentiator: it increases the body's energy expenditure rather than only suppressing appetite. I prescribe it off-label after a full medical intake, and I walk every patient through the trial data, and what's still unknown, before we start.”
Dr. Patrick Taylor, MD · Live Vital physician
About Retatrutide.
Also known as: LY3437943, Reta
Retatrutide is a triple-receptor agonist, developed by Eli Lilly, that activates the GIP, GLP-1, and glucagon receptors simultaneously. Where tirzepatide activates two of these receptors, retatrutide adds glucagon receptor activation, which appears to increase the body's energy expenditure rather than only reducing appetite. In a Phase 2 trial published in the New England Journal of Medicine, the highest-dose group lost an average of approximately 24% of body weight at 48 weeks, more than has been reported for any other agent in this class to date.
Retatrutide is not FDA-approved for weight management and remains in Phase 3 clinical trials for that indication. Live Vital offers retatrutide as a compounded medication, prescribed off-label by Dr. Taylor after a complete medical intake and your informed consent, for patients who want to discuss whether an emerging triple-agonist therapy fits their metabolic health goals.
How it works
Retatrutide activates three separate receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and the glucagon receptor. GIP and GLP-1 activation reduce appetite and improve the body's insulin response, the same basic mechanism behind dual-agonist drugs like tirzepatide. The added glucagon receptor activity increases hepatic energy expenditure, promotes lipolysis (the breakdown of stored fat), and reduces liver fat, which is why it is also being studied for metabolic-associated fatty liver disease (MASLD).
Who it may help.
- Individuals who have plateaued on GLP-1 or dual-agonist (tirzepatide) therapy and want to discuss additional options
- People with metabolic-associated fatty liver disease (MASLD) alongside excess weight
- Those with obesity and type 2 diabetes seeking more aggressive metabolic support
- People interested in an emerging triple-agonist therapy who want to review the trial data and off-label option with a physician
What to expect, when.
In Phase 2 trials, participants often reported reduced appetite within the first few weeks, with meaningful weight loss typically evident by around 12 weeks and continuing through the 48-week trial period, where the highest-dose group averaged approximately 24% body weight reduction. Retatrutide remains in Phase 3 trials for weight management and is not FDA-approved for this use. Individual results vary, and your experience will depend on your health history and how your body responds under Dr. Taylor's supervision.
Dosing is not one-size-fits-all. Dr. Taylor personalizes your dose and schedule after your medical intake, and adjusts it as your protocol progresses.
Safety information.
Possible side effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
- Dyspepsia
- Injection site reactions
- Increased heart rate
Who should talk to us first
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- History of severe pancreatitis
- Pregnancy or breastfeeding
- Severe gastrointestinal disease
This information is educational and is not a substitute for medical advice. Every protocol requires a medical intake and physician approval, and outcomes vary by individual.
Standard with every plan.
Doctor-prescribed
Prescribed through Live Vital’s licensed clinical team.
Licensed US pharmacy
Prepared by a licensed US pharmacy and shipped to you.
Unlimited messaging
Reach our care team directly with questions at any time.